Friday, 8 April 2016

Oxford debate: this house believes that over engineered  clinical development has inhibited innovation

Panellists: Bettina Ryll (Founder of Melanoma Patient Network Europe) Martin Landray (University of Oxford),  Mike Ryan (Medidata Solution), Sam Wadsworth (Dimension Therapeutic) -session chair Jullianne Hull

Mike Ryan
innovation -new ideas
new implies taking risks
regulatory authorities are seeing that as a risk
scientific advices -helpful but time consuming

Martin Landray
To engineer- a methodological approach to integrate elements
there is prudence in engineering in the context of CT
-is quality of clinical design, involving all stakeholders including pts and public
a critical thinking
we should stop to do things that we suppose others are expecting from us
over engineering is not the problem, but forget engineering is the problem
CTs (clinical trials) -have to integrate a critical human element,
each element can be subject of engineering
we live in imperfect world
we do need systems to review errors
''I have heard from Pharma that the new technology are inducing undetermined risks '' so better to not go for new technologies.. is the necessity for innovation

Sam Wadsworth
looking to 20 years clinical trials experience
how we engineer clinical trials now
the number of CTs has increased
but the number of new drug approved has decreased
we are asking pts (patients) to take procedures which are not necessary (?!)
Pts and doctors are finding impossible to run CTs
Interactions with specific IT tools within CTs is difficult for doctors/investigators (!)

Bettina Ryll
Not true-the above assertion confounds symptoms with the cause
Innovation in health improves clinical efficacy, cost effectiveness, pharmacovigilance,
Innovation is there to bring timely access to the good drugs to the patients.
Innovation has to be accessible in the right time and for all! ..
Clinical trials with a bad design  -from the day they start everybody knows that half of our people would die on inferior comparators: this has to stop and we have to ask ourself for what and for whom we are doing this, what are our real goals.
Innovation has to be sustainable

Regulators comments
The most problems come not for engineering the trials but from designing bad protocols
We have to ask yourself if what we do is meaningful for the research -engineering just for engineering is not the way to go

Statistician view -poor quality of clinical trials in phase II compromises in fact the entire protocol design -should really learn from phase II in order to design properly phase III

''Just think!...'' (Martin Landray)


Friday, 14.00- 15.30

Session to give an update on ADAPT SMART is an enabling platform for the coordination of MAPPS (Medicines Adaptive Pathways to Patients ) previously called Adaptive LicensingMPA


MAPPS are a concept that, based on scientific innovation, procide timely access to specific medicines, with a potential to address unmet need(s) in a specific, well-defined patient populations in a sustainable way.

ADAPT SMART is a support tool to MAPPS.

Ad Schuurman- Dutch payer

Very interesting to listen to a payer's perspective on MAPPS and the specific issues a payer faces. Volume control

Adaptive show-stoppers

- prevent decline in quality of evidence
- cost control
- want to restrict MAPPS to special cases:
  • patients who cannot wait
  • deteriorate irreversibly or die
  • urgent public health protection
  • major improvement expected
realistic exit strategy.

Thursday, 7 April 2016

Start-ups with regulatory and industry- small biotech companies potential to develop treatments - Session 0104

How can idea from academia can be better translated to novel treatment options

Important to give a chance to thesmall companies- they are the ones developing new compounds/drugs that are later bought by Big Pharma.
Small companies challenges (finances and innovation)
New treatments paradigms

Andreas Schmidt CEO AYOXXA Biosystems Germany (35 people)
interest in huge topics
medical decision based on proteomics
company interested in genomics and proteomics
ambition to base clinical trials on proteomics
access to clinical samples
to identify which patients are going to respond (biomarkers)

Sam Wadsworth, Dimension Therapeutic
2013 -company was funded
partnership with big companies (e g. Bayer)
partnership with academics
partnership is bringing money and/or validation
clinical trials- small trials (phase I, II)
gene therapy -challenge for a small companies, few receive positive recommendation by EMA
focus on one topic is better

Melanie Carr, EMA -European Medicine Agency
why is important to support small companies
90% -commercialised by big pharma
no product commercialised by academia
but the true is that less than half health technologies are coming  from big companies
Innovation Task Force -early guidance how companies can be embarked in development programs
Difficult to comply with EU regulations
Plan Management Risks has to be included in the projects of small companies

Dr. . Kalkbrenner,  Boehringer Ingelheim
Company Bayer -life science companies -pharma component
Grants4Apps, funding and supporting small companies (?)

Adaptive Pathways and conditional approval

Thursday, 16.00

Francois Houyez

Valid point
differences in compassionate usage programs between countries effectively create disparity in access across Europe, even between countries with similarly efficient healthcare systems. Francois mentioned 4 years- but need to verify in which setting.



Tomas Salmonson

conditional earlier approval can make it difficult to recruit for the registration trials. And I wonder why that is!!! Guess the trial design is not attractive for patients? 

Susan Forda

comparison between US and EU approvals of innovative therapies-

for indications that let to special pathways for both sides.

US has more fast access designations than the EU

US takes less time to approval than EU

BUT less post-marketing studies in the EU than in the US. 

And- faster approval does not lead to more withdrawls
So far, no withdrawl after accelerated approval/ conditional approval. In the US, none on break-through and one withdrawl for a priority review!

Niklas Hedberg, TLV

used a great analogy of a stream to describe how new therapies come down after a damm (the regulators) and how the downstream tries to cope.

Hans-Georg Eichler

Use of real-world data in the Adaptive Pathways pilots

and again the very valid point that IF registries, they need to have the right quality

interesting enough, this is an adaptive pathway discussion and the first comment goes directly to drug prices. Niklas made the point that there is the worry that adaptive licensing effectively out-sources part of the development cost to society (instead of the company paying for it). 
Very valid point by Tomas Salmonson- what is the point if we approve drugs for a wide indication (like HepC) but then only give them to a few patients because of price? That makes no sense from a public health perspective!

Niklas, TLV, suggestion to discuss conditions with a consortium of different Pharma working in that space to discuss the specific challenges and needs way before a single products hits the market.

Why involve patients in Rare Disease Research

The Genetic Alliance
Patient voice

Rare disease condition
understand the condition
define the question
plan the strategy
recruit the volunteers
validate the outcomes
help secure implementation

we move in a era of full  scientific advances
with  advance of personalised medicine-small and careful defined populations are much more likely to get benefits from the drug that  is administered

Clinical data is based on number-are important-but what that numbers means in real life?
Numerical changes have impact of quality of life for pts* and their families

we have NO interest in poor quality science
Involvement in judging research proposal
is this a relevant question for us?
working with James Lind Alliance-involvement of pts pushed-up the quality of research

How pts can help?

Research Priority Settings
Donors -have interest to see where the money goes
Realism -tangible deliverable related to our experience, to things that matter t us
Results -Eurogentest-what patients want to know, but not what clinicians think is the ought to go

Citizen jury
Close relationship with the pts and their families

About EUPATI- expertise is needed; skills to have to conversation with regulators, clinicians, payers..etc.

''We are not experts in everything but neither are you!''
We can tell you what is important for us, but not how to use the statistical tools -this is the job you are paid to do..


Innovative ways of involving patients in RD

The industry view 
Tony Hoos, Amgen

We all serve patients& society (?)
Patient -consumer/Peer
Patient involvement consideration

strategic document
strategic purpose
R-D. Life cycle (R_D, Life cycle management)

Where there opportunities for patients involvement
insert slide (red)
meaningful pts involvement -which stages

enhance pts access
embrace pts centric healthcare
facilitate coordination  and integration of pts data -un-bias info
acquire and develop talent
do we have the right talent to interact with pts organisation?

evolution of pts engagement
number of pts involved increased
FDA strategic priorities

Shall HTA depend on RCT (randomised controlled trilas) or RWD (real world data) or both?

Thursday, 14.00- 15.30

Chris Chinn, Head of Real World Investigations, Sanofi and GetReal 

outcome- comparator- patients- intervention

Outcomes are affected by patient behaviour, physician behaviour and the healthcare system and not all of these can be measured in a clinical trial.


RCT to inform clinical effectiveness
Observational study for budget impact

integrate both data sets using network meta analysis (NESTA involved in this- worth checking out!)

TWiCS- run a randomised trial within an observational cohort, using the registry as a whole as control. group in Manchester, failed to capture name


In the end, patients make personal risk- benefit assessments: are the benefits of the drug out-weighing the risks? That then affects the effectiveness of the treatment.

So in my mind, we would have to worry less about the gap between effectiveness (drug in the real world) and efficacy (drug in a clinical trial) if we paid more to those personal-risk assessments EARLY ON.

PAES- Post-Authorisation Efficacy Studies - applying RCT standards to RWD

Giovanni Tafuri, EMA

uncertainties about drug efficacy stem from:
  • (sub-)populations studies
  • endpoints
  • long term use of a product
  • co-treatment with other products
  • real life usage
  • change in the understanding of a disease or a drug
  • change in scientific factors for previous efficacy 

choice of study design depends on the need and can include:
  • randomised trials
  • non-randomised trials
  • explanatory trials
  • pragmatic trials
  • observational trials

Data sources-

1. can be collected for the purpose: clinical trials

2. analyze existing data- e.g. registries, electronic Health records

Importance to agree on a design prior to starting and the place of real world data during the life cycle of the product: worth noting the registries.

The PARENT joint action patient registry initiative: purpose to reduce duplication between registries. Worth looking up!

And important- who sets the standards for the registries?

Comment of Guido Rasi, EMA- we need to define what real world data means

Conducting HTA using RWD (real world data)

Francois Meyer, HAS

Achievements of EUnetHTA

1. Database EVIDENT - HTA bodies can find out what others have collected


3. position papers on research recommendations

  • how to best formulate research recommendations
  • how to decide on the appropriate study design to answer those questions
4. core protocol pilot for AEG (additional evidence generation)
first pilot of a joint HTA process
would be worth looking this up- and see whether we agree or not


Comment from Chris Chin
When to set up a registry? At launch of a product is too late- one should start earlier, so that there is a good quality registry in place at launch and one can focus on answering questions!

Luca Pani, AIFA
differential MEA in place in Italy with the existing registry - a different MEA (management entry agreement) for every indication of the same drug
it has been a major investment for the healthcare system to have a registry of this granularity and quality standards but he thinks it has paid of!